Deconib SA
1.0 FTEDeconib reported total assets of €9.65m at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Aug 2026), with 1 full-time equivalent.
The score of Deconib shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -6 % Total assets +13 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Deconib's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Aug 2026
- Year ended 31 Dec 2024filed on 27 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
- Year ended 31 Dec 2021filed on 16 Aug 2022
Deconib's financial analysis
- Solvency34.0%sector median: 55.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Deconib
Deconib's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0425.919.575
- VAT number
- BE0425919575
- Peppol
- Registered · 0208:0425919575 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 21 Dec 1983
- Registered office
- 9990 Maldegem
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 29 Aug 2026
- Activity
- Activities of holding companies (NACE 64210)
Deconib (SA) has been based in Maldegem since 1983, active in: activities of holding companies. For 2025, it reports a net profit of 279,063 € and equity of €3.29m; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 34.0%, below the median of its sector (55.6%).
Companies similar to Deconib
Companies in the same business, of comparable size and area, outside its group.
- A.A.F. - Invest Activities of holding companies Houthulst · balance sheet €11.9m
- Aircasell Activities of holding companies Ardooie · balance sheet €10.4m
- Crea Invest Activities of holding companies Wuustwezel · balance sheet €8.21m
- Matratex Activities of holding companies Kuurne · balance sheet €13.8m
- Bekas Group Activities of holding companies Leuven · balance sheet €11.5m
- Quebec Activities of holding companies Langemark-Poelkapelle · balance sheet €8.38m
- Mountville Mills Europe Activities of holding companies Ronse · balance sheet €13.6m
- Ivens Management Activities of holding companies Antwerp · balance sheet €11.8m
Frequently asked questions about Deconib
What is the revenue of Deconib?
Deconib files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Deconib?
In Belgium, the VAT number is the company number prefixed with BE: BE0425919575 for Deconib, if the company is VAT-registered. Its company number (CBE) is 0425.919.575.
Where is the registered office of Deconib?
According to the CBE register, the registered office of Deconib is in 9990 Maldegem.
What is the equity of Deconib?
At the close of the 2025 financial year, the equity of Deconib amounts to 3,286,445 €, a solvency of 34.0% of total assets.
How many people work at Deconib?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Deconib?
The register lists 6 active mandates at Deconib. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Deconib
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →